


What is claimed:

1. A compound of Formula I



5

or a pharmaceutically acceptable salt thereof, wherein:

R₁ is selected from the group consisting of H or methyl; and

R₂ is selected from the group consisting of H or methyl.

2. The compound as recited in claim 1 wherein:

R₁ is H; and

R₂ is selected from the group consisting of H or methyl.

3. The compound as recited in claim 1 wherein:

R₁ is H; and

R₂ is H.

4. The compound as recited in claim 1 wherein:

R₁ is H; and

R₂ is methyl.

5. The compound as recited in claim 1 wherein:

R₁ is methyl; and

R₂ is hydrogen or methyl.

6. The compound as recited in claim 1 wherein:

R₁ is methyl; and

R₂ is H.

7. The compound as recited in claim 1 wherein:

R₁ is methyl; and


R₂ is methyl.

8. The compound as recited in claim 1 wherein:

R_1 is selected from the group consisting of \overline{H} or methyl; and

R_2 is H.

9. The compound as recited in claim 1 corresponding to Formula II



II

or a pharmaceutically acceptable salt thereof, wherein:

R_1 is selected from the group consisting of H and methyl; and

R_2 is selected from the group consisting of H and methyl.

10. The compound as recited in claim 9 wherein:

R_1 is H; and

R_2 is selected from the group consisting of H and methyl.

11. The compound as recited in claim 9 wherein:

R_1 is H; and

R_2 is H.

12. The compound as recited in claim 9 wherein:

R_1 is H; and

R_2 is methyl.

13. The compound as recited in claim 9 wherein:

R_1 is methyl; and

R_2 is selected from the group consisting of H and methyl.

14. The compound as recited in claim 9 wherein:

R₁ is methyl; and

R₂ is H.

5

15. The compound as recited in claim 9 wherein:

R₁ is methyl; and

R₂ is methyl.


10

16. The compound as recited in claim 9 wherein:

R₁ is selected from the group consisting of H and methyl; and

R₂ is H.

17. The compound as recited in claim 1 corresponding to Formula III:



or a pharmaceutically acceptable salt thereof, wherein:

R₁ is selected from the group consisting of H and methyl; and

R₂ is selected from the group consisting of H and methyl.

20

18. The compound as recited in claim 17 wherein:

R₁ is H; and

R₂ is selected from the group consisting of H and methyl.

19. The compound as recited in claim 17 wherein:

R₁ is H; and

25

R₂ is H.

20. The compound as recited in claim 17 wherein:

R₁ is H; and

R₂ is methyl.

21. The compound as recited in claim 17 wherein:

R₁ is methyl; and

5 R₂ is selected from the group consisting of H and methyl.

22. The compound as recited in claim 17 wherein:

R₁ is methyl; and

R₂ is H.

23. The compound as recited in claim 17 wherein:

10 R₁ is methyl; and

R₂ is methyl.

24. The compound as recited in claim 17 wherein:

R₁ is selected from the group consisting of H and methyl; and

R₂ is H.

25. A compound as recited in claim 1 wherein the compound is the S enantiomer.

25 A compound as recited in claim 1 wherein the compound is the R enantiomer.

20 26 A compound as recited in claim 1 wherein the compound is the E isomer.

27. A compound as recited in claim 1 wherein the compound is the Z isomer.

28. A compound selected from the group consisting of:

25 (2S, 4E)-2-Amino-6-(1-iminoethylamino)-hept-4-enoic acid;

(2S, 4Z)-Amino-6-(1-iminoethylamino)-hept-4-enoic acid;

(2 R/S, 4E)-Amino-4,5-dimethyl-6-(1-iminoethylamino)-hept-4-enoic acid;

(2 R/S, 4Z)-Amino-4,5-dimethyl-6-(1-iminoethylamino)-hept-4-enoic acid;

(2S, 4E)-Amino-4-methyl-6-(1-iminoethylamino)-hept-4-enoic acid;

(2S, 4Z)-Amino-4-methyl-6-(1-iminoethylamino)-hept-4-enoic acid;
(2S, 4E)-Amino-5-methyl-6-(1-iminoethylamino)-hept-4-enoic acid;
(2S, 4Z)-Amino-5-methyl-6-(1-iminoethylamino)-hept-4-enoic acid;
(2R, 4E)-2-Amino-6-(1-iminoethylamino)-hept-4-enoic acid; and
5 (2R, 4Z)-Amino-6-(1-iminoethylamino)-hept-4-enoic acid.

29. A pharmaceutical composition comprising a compound of claim 1.

30 A method of inhibiting nitric oxide synthesis in a subject in need of such
10 inhibition by administering a therapeutically effective amount of a compound of claim 1.

31. The method as recited in claim 30 wherein said nitric oxide synthase is an
inducible nitric oxide synthase isoform, said inhibition selective for inducible nitric oxide
synthase over the constitutive forms of nitric oxide synthase in a subject in need of such
15 inhibition.